INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $4,491,000 | +94.8% | 175,000 | +16.7% | 0.05% | +112.0% |
| Q1 2020 | $2,306,000 | -29.6% | 150,000 | -33.7% | 0.02% | +47.1% |
| Q4 2017 | $3,275,000 | -62.3% | 226,160 | -58.9% | 0.02% | -55.3% |
| Q3 2017 | $8,679,000 | +4113.1% | 550,000 | +7332.4% | 0.04% | +1166.7% |
| Q1 2016 | $206,000 | -10.8% | 7,400 | +72.1% | 0.00% | +50.0% |
| Q4 2015 | $231,000 | -94.0% | 4,300 | -95.5% | 0.00% | -95.6% |
| Q3 2015 | $3,832,000 | – | 95,700 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |